Caranx Medical Announces FDA Submission of TAVIPILOT Soft: the World’s first AI Software for Real-time Intra-operative Guidance of Transcatheter Heart Valve Implantation
24.1.2025 09:00:00 CET | Business Wire | Press release
Caranx Medical (“Caranx”), a French medical device company specializing in the development of an autonomous robot to democratize access to Transcatheter Aortic Valve Implantation (TAVI), a lifesaving procedure, today announced FDA submission of the world first AI Software for real-time intra-operative guidance of transcatheter heart valve implantation.
The FDA submission marks a significant milestone of Caranx strategy towards planned market introduction of TAVIPILOT Soft by end of 2025.
“The team at Caranx has achieved an important milestone in the submission to the Food and Drug Administration, FDA. This extremely promising step paves the way to early commercialization of the TAVIPILOT Soft by end 2025. I am very excited about the real-time guidance of TAVI/TAVR, a key to accurate and precise positioning of the heart valve as well as the promotion of potentially more predictable and controlled valve deployment” says CEO of Caranx Jorgen Hansen
“Allowing a broader number of cardiologists, surgeons and interventional cardiology centers to perform complex procedures, such as TAVI, the Caranx AI-driven software and autonomous robot is at the heart of our mission of entrepreneurs and business builders to save lives and revolutionize medicine” says Philippe Pouletty, MD, founder of Caranx and CEO of Truffle Capital
“This first release of our TAVIPILOT software marks an important step toward AI-augmented procedures. Our software is designed to be user-friendly, ensuring that cardiologists and surgeons can integrate it seamlessly into their usual practice. TAVIPILOT Soft allows clinicians to position a prosthetic valve easily and with high precision, ensuring that more patients could benefit from a high quality of care.” says Caranx co-founder and CTO Pierre Berthet-Rayne
“TAVIPILOT soft is a breakthrough for TAVI procedures, providing millimetric precision using augmented reality. Clinicians use precise preoperative images (CT-scan) for the planning of TAVI. However, during the procedure, they rely only on fluoroscopy, which shows the anatomy indirectly (requiring contrast injection) and transiently. Accurately positioning the valve requires long training and experience. Our TAVIPILOT Soft identifies key heart anatomical features for precise valve placement and is expected to transform TAVI procedures for patients and clinicians” says Caranx co-founder and CMO Eric Sejor.
The TAVI procedure was introduced app. 20 years ago, and still critical challenges and long learning curves are faced by cardiologists and surgeons during these procedures for a precise and accurate delivery of the heart valve. While 300.000 TAVI procedures are performed annually in the USA and EU, 1.700.000 patients are in need of a TAVI procedure. According to Frost and Sullivan, the current TAVI market is $8Bn growing double digits annually. Caranx products could broadly increase the number of patients benefiting from TAVI.
TAVIPILOT Soft is an easy-to-use, AI-driven intra-operative software which tracks real-time anatomical and instrument landmarks. It enables precise and accurate heart valve positioning and delivery. TAVIPILOT Soft is expected to be a revolution for the transcatheter replacement of aortic valves, which is limited today because it is reserved for the most experienced cardiologists and centers. TAVIPILOT Soft is compatible with all cardiac Imaging Systems and will be compatible with principal TAVI heart valves on the market.
“At Caranx Medical, our vision extends to developing our Artificial Intelligence Platform, currently containing more than 5000 annotated multimodality images of CT, Fluoroscopy, Echo, data, etc. used to feed our AI algorithms and to revolutionize other cardiovascular indications, such as mitral and tricuspid valve replacements, reshaping the landscape of interventional medicine” says CEO of Caranx, Jorgen HANSEN
*****
About Caranx Medical
Backed by a team of top-tier experts, management team and supported by Truffle Capital, a renowned name in European biotech and MedTech investment, Caranx Medical is a French MedTech company, founded by Philippe Pouletty, MD, CEO of Truffle Capital, cofounded by CMO Eric Sejor, MD, and CTO Pierre Berthet-Rayne. Caranx has the ambition to become a global leader in AI and robotic assisted transcatheter heart valve implantation.
Subject to bringing TAVI PILOT Robotic solution with autonomous control to First in Human in 2025, Caranx ambition is to gradually commercialize its products and is poised for rapid growth.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250124801853/en/
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Pacífico Mexinol Celebrates the Symbolic Groundbreaking in Topolobampo, Positioning Mexico in the New Low-Carbon Chemical Industry24.4.2026 02:29:00 CEST | Press release
The initiative brings together governments, diplomats, and global investors around a Net Zero industrial model. The project establishes Topolobampo, Sinaloa as a key hub for industrial development in North America. The Pacifico Mexinol project (“Mexinol”) celebrated the beginning of its pre-construction phase by symbolically laying a first stone, marking the start of one of the most significant global industrial investments in blue and ultra-low carbon methanol. The event brought together diplomats, authorities, and national and international business leaders, reflecting the project’s strategic importance for Mexico and its integration into the emerging low-carbon economy. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423775301/en/ Adolfo Murietta, Project Shareholder; Rommel Gallo, CEO Transition Industries; Ron Johnson, United States Ambassador to Mexico; Drew Hoster, Counsel General of the United States in Hermosillo,
The New World ID: Proof of Human for the AI Era Scales Across the Digital Platforms People and Businesses Use Every Day24.4.2026 02:20:00 CEST | Press release
Docusign, Okta, Tinder, Vercel, and Zoom bring World ID proof of human to businesses, AI agents, and consumers Last week, World announced the next generation of World ID, its proof of human protocol, designed to increase trust on the internet. The announcement was made during “Lift Off,” a live event in San Francisco. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260417530721/en/ Docusign, Okta, Tinder, Vercel, and Zoom bring World ID proof of human to businesses, AI agents, and consumers As AI makes it easier than ever to generate convincing content, identities, and interactions, trust online has decreased. World ID addresses this challenge by enabling individuals to privately prove they are a real, unique human, without revealing their identity across apps, platforms, and services. “If anything online can be faked, you no longer know who or what to trust,” said Tiago Sada, Chief Product Officer at Tools for Humanity, a co
Cognite Positioned as a Front Runner in LNS Research Solution Selection Matrix for Industrial AI Platforms23.4.2026 20:00:00 CEST | Press release
Cognite, the global leader in Industrial AI, has been named a Front Runner in the LNS Research Solution Selection Matrix for Industrial AI Platforms (SSM). The LNS Research SSM evaluates vendors using a rigorous methodology that leverages its “3P” framework—Product, Potential, and Presence—to assess both current capabilities and future readiness. Within the report, Cognite is recognized in three key areas: depth in user-centric industrial AI applications, its knowledge graph-based data model, and its strong partner ecosystem. Together, all three give Cognite the ability to unify and contextualize complex industrial data, enabling organizations to operationalize AI at scale. “Cognite brings a sophisticated data model built for industrial complexities, along with advanced analytics and AI-driven insights, which is crucial for industrial organizations to achieve meaningful productivity gains and enterprise-wide ROI,” said Vivek Murugesan, Research Analyst at LNS Research. “These capabilit
Venture Global Announces Closing of $750,000,000 Senior Secured Notes by Venture Global Calcasieu Pass, LLC23.4.2026 19:47:00 CEST | Press release
Venture Global, Inc. (“Venture Global”, NYSE: VG) announced today that its subsidiary, Venture Global Calcasieu Pass, LLC (“VGCP”) has closed an offering of $750,000,000 aggregate principal amount of 6.000% senior secured notes due 2036 (the “Notes”). The Notes will mature on May 1, 2036. VGCP used the net proceeds from the offering, together with cash on hand and proceeds received from certain hedge terminations, for the prepayment, in full, of VGCP’s outstanding term loans, and to pay fees and expenses in connection with the offering. The Notes are guaranteed by TransCameron Pipeline, LLC (VGCP’s affiliate). The Notes are secured on a pari passu basis by a first-priority security interest in the assets that secure VGCP’s existing senior secured first lien credit facilities and VGCP’s existing senior secured notes. The Notes were not registered under the Securities Act of 1933, as amended (the “Securities Act”) or the securities laws of any state or other jurisdictions, and the Notes
Does Muscle Composition Identify High-Risk Individuals in Chronic Kidney Disease? New AMRA Medical Study Says Yes, Reveals Strong Link to Mortality23.4.2026 17:10:00 CEST | Press release
AMRA Medical researchers recently set out to answer the question: what is the relationship between adverse muscle composition (AMC) and mortality in kidney disease? Recent findings demonstrate that AMC, characterized by low muscle volume z-score and high muscle fat infiltration, is an independent and strong predictor of all-cause mortality in individuals with chronic kidney disease (CKD). The findings, published in Clinical Journal of the American Society of Nephrology, were based on data from the UK Biobank imaging study and further reinforce the clinical relevance of MRI-derived muscle biomarkers in identifying high-risk populations across chronic diseases. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260423198497/en/ AMRA's MRI-based muscle biomarkers in clinical trials Researchers from AMRA, alongside our collaborators at Linköping University (LiU), analyzed 894 participants with CKD using AMRA’s MRI-based body composi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom